ClinicalTrials.gg
Not yet recruitingNCT07240805Updated Oct 13, 2026

Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies

An observational study in Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB) and PSP, sponsored by BioSensics. Not yet recruiting at 2 sites in United States. Open to participants aged 40 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by BioSensics · Observational

How we know

Updated Oct 13, 2026Start date movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
40 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 84 studies in Supranuclear Palsy, Progressive with a site in United States — 19 open to participants now, 25 under way, 1 of them phase 3. Supranuclear Palsy, Progressive · United States.

Planned enrollment
24th of 31
60 · median 200
Started
2027
the only one that year
Observational
31 of 84
10 open now
Primary completion
2028-12
later than 11 of 24 live
Registered
79th of 84
by date

Among the 84 studies in Supranuclear Palsy, Progressive with a site in United States, this one is the 24th largest by planned enrollment of the 31 observational ones that give a count, is the only one that started in 2027, is one of 31 observational ones, reaches primary completion later than 11 of the 24 other live ones, and was the 79th registered.

Supranuclear Palsy, Progressive

171 studies on the registry are indexed under Supranuclear Palsy, Progressive; 51 are open to participants now.

Browse Supranuclear Palsy, Progressive studies →

Open to participants now

19 of the 84 studies in Supranuclear Palsy, Progressive with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Supranuclear Palsy, Progressive studies recruiting now, 22 (58%) set no upper age limit and 2 (5%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.

This study: 40 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Supranuclear Palsy, Progressive with a site in United States, or all of them as a file.
02

Study summary

Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily function. Researchers at BioSensics, Johns Hopkins School of Medicine, Massachusetts General Hospital and their collaborators aim to conduct an analytical and clinical validation of wearable-based digital health technologies for monitoring upper and lower limb function in PSP, MCI-LB and DLB that could enable frequent, at-home monitoring and be incorporated into future clinical trials.

Read the detailed description

PSP is a severe and rapidly progressive frontotemporal lobar degeneration (FTLD) syndrome that lacks effective treatment and leads to a rapid onset of dementia, disability, and eventually death. Dementia with Lewy bodies (DLB) is the second most common type of neurodegenerative dementia after Alzheimer's disease that severely impacts daily function and shortens lifespan. Mild cognitive impairment with Lewy bodies (MCI-LB) is an earlier stage where cognitive impairment is noticeable, but does not significantly interfere with living to the degree as seen in DLB. Both PSP and DLB cause significant motor impairment, resulting in progressive loss of independence in activities of daily living, such as eating, dressing, and writing. Despite approximately 200 ongoing clinical trials in PSP and DLB, there are no FDA-approved treatments for FTLD syndromes (including PSP) or DLB. One of the key challenges in the development of new effective therapies for DLB syndromes is the lack of validated instruments and biomarkers to measure disease severity, disease progression, and the effect of therapeutic interventions. Clinical measures of PSP and DLB, largely based on quantitative variations on the neurological exam, have suboptimal sensitivity to change and relevance to clinical meaning in patients' lives. Since 2019, BioSensics, MGH and JHU have partnered to develop a remote monitoring solution for FTLD syndromes using wearable sensors and a series of digital assessments. The solution uses PAMSys, a FDA-listed Class II pendant sensor for monitoring physical activity, posture, and walking parameters during activities of daily living, where the investigators have demonstrated the feasibility of using PAMSys for tracking ambulatory change in PSP. In this project, the investigators will use PAMSys pendant, PAMSys ULM wrist sensors, and PAMSys Gait ankle sensors to enable comprehensive monitoring of upper and lower limb function in PSP and DLB. The will demonstrate the accuracy (analytical validation) of PAMSys, PAMSys ULM and PAMSys Gait sensors in PSP and DLB. Digital speech, fine motor control, and cognitive assessment data will also be collected from the participants using a study tablet. In addition, a proof-of-concept study will be conducted to demonstrate the feasibility and reliability of monitoring motor function in PSP and DLB using the wearable sensors. Clinically, the proposed solution can be used to develop more sensitive approaches to monitor an individual's response to new therapies. Such solutions can enable the detection of subtle changes in movement, ambulation, and motor function while providing specific individualized insights into the clinical phase of disease. Additionally, by testing whether disease outcomes can be measured remotely in patients' homes, this project will be a crucial step forward for both research and clinical care that could meaningfully reduce both financial and time costs for patients, clinicians, researchers, and pharmaceutical companies.

03

Conditions studied

  • Progressive Supranuclear Palsy(PSP)
  • Dementia With Lewy Bodies (DLB)
  • PSP
  • Lewy Body Dementia (LBD)
  • Lewy Body Disease
04

Who can participate

Ages eligible
40 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals with clinical diagnostic criteria for probable PSP, probable MCI-LB or probable DLB

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants aged 40-89 meeting clinical diagnostic criteria for probable PSP, probable MCI-LB or probable DLB.
  • Able to be present for all study procedures, complete questionnaires and assist during home data collection.
  • Eligible participants must be fluent in reading and speaking English and must be capable of providing based on the principal investigator's judgment.
  • Must have a caregiver or study partner who is willing and able to assist with all study-related procedures.
  • Ambulatory (able to take 10 steps with minimal support such as use of a cane)

Exclusion criteria

Exclusion Criteria:

  • Any neurological, medical, or psychiatric condition that would preclude or confound participation in study activities based on the investigator's judgment.
  • History of frequent falls defined as more than 5 falls per month, will not be eligible to participate in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Progressive Supranuclear Palsy (PSP)

    30 patients meeting clinical diagnostic criteria for probable Progressive Supranuclear Palsy will be recruited for the study

  • Dementia with Lewy Bodies (DLB) and Mild Cognitive Impairment with Lewy Bodies (MCI-LB)

    30 patients meeting clinical diagnostic criteria for probable MCI-LB or DLB will be recruited into the study

06

What researchers measure

Primary outcomes

  1. 2-Minute Walk Test (2MWT)

    Participants will perform the 2-minute walk test (2MWT) while wearing a PAMSys pendant sensor, and two PAMSys Gait ankle sensors.

    Time frame: Baseline.

  2. Timed Up & Go Test (TUG)

    Participants will perform the (TUG) test while wearing a PAMSys pendant sensor, and two PAMSys Gait ankle sensors.

    Time frame: Baseline.

  3. 5-times Sit-to-Stand Test (5xSTS)

    Participants will perform the 5-times Sit-to-Stand Test (5xSTS) while wearing a PAMSys pendant sensor.

    Time frame: Baseline.

  4. Box and Block test (BBT)

    Participants will perform the Box and Block test (BBT) while wearing two PAMSys ULM wrist sensors.

    Time frame: Baseline.

  5. 9-Hole Peg Test (9HPT)

    Participants will perform the 9-Hole Peg Test (9HPT) while wearing two PAMSys ULM wrist sensors.

    Time frame: Baseline

  6. Physical Activity Monitoring

    Following the baseline visit, participants will be asked to wear a PAMSys pendant sensor for 14 days at home. The average daily number of steps will be measured using the PAMSys pendant.

    Time frame: 14 days

  7. Gait Monitoring

    Following the baseline visit, participants will be asked to wear two PAMSys Gait ankle sensors for 14 days at home. Daily average stride velocity will be measured using the PAMSys Gait ankle sensors. The stride velocity unit is m/s.

    Time frame: 14 days

  8. Hand Function Monitoring

    Following the baseline visit, participants will be asked to wear two PAMSys ULM wrist sensors for 14 days at home. Average daily number of hand goal-directed movements will be measured using the AMSys ULM wrist sensors.

    Time frame: 14 days

Secondary outcomes

  1. Schwab and England Activities of Daily Living (SE-ADL)

    This is a standard patient-reported outcome to measure of functional ability. The SE-ADL scores range from 0%-100%, where 0% represents a worse outcome.

    Time frame: Baseline.

  2. Zaret Burden Interview (ZBI)

    The ZBI is completed by a reliable caregiver. The ZBI scores range from 0-88, where 88 represents a worse outcome.

    Time frame: Baseline.

  3. Symbol Digit Modalities Test (SDMT)

    This brief cognitive test examines processing speed and sustained attention.

    Time frame: Baseline.

  4. Montreal Cognitive Assessment (MoCA)

    This is a brief global cognitive screening assessment. Scores range from 0 to 30 where 0 represents a worse outcome.

    Time frame: Baseline.

  5. Patient Global Impression Scale (PGIS)

    This is a brief patient-reported global assessment of disease severity. Participants rate their condition from 0 (no severity) to 5 (very severe).

    Time frame: Baseline.

Other outcomes

  1. Digital Speech Assessment

    Using a study tablet, participants will perform a series of digital speech assessments. The collected speech data will be analyzed using BioDigit Speech, an automatic speech analysis software developed by BioSensics.

    Time frame: Baseline.

  2. Digital Cognitive Assessment

    Using a study tablet, participants will perform a series of digital cognitive assessments.

    Time frame: Baseline.

  3. Digital Fine Motor Control Assessment

    Using a study tablet, participants will perform a series of tapping tests.

    Time frame: Baseline.

07

Study locations

2 sites
08

References and documents

Publications

  • Nunes AS, Yildiz Potter I, Mishra RK, Bonato P, Vaziri A. A deep learning wearable-based solution for continuous at-home monitoring of upper limb goal-directed movements. Front Neurol. 2024 Jan 5;14:1295132. doi: 10.3389/fneur.2023.1295132. eCollection 2023. PubMed 38249724 ↗
  • Sharma M, Mishra RK, Hall AJ, Casado J, Cole R, Nunes AS, Barchard G, Vaziri A, Pantelyat A, Wills AM. Remote at-home wearable-based gait assessments in Progressive Supranuclear Palsy compared to Parkinson's Disease. BMC Neurol. 2023 Dec 11;23(1):434. doi: 10.1186/s12883-023-03466-2. PubMed 38082255 ↗

Individual participant data

Plan to share: Yes — All dataset(s) that can be shared will be deposited in NeuroBANK™. NeuroBANK is a patient-centric clinical research platform that allows capture and aggregation of clinical and clinical research data from simultaneously running research projects and links these data with biospecimen repositories, image banks and genetic information. The database is built upon Chapter 21 CFR Part 11 compliant features. NeuroBANK is hosted and maintained by the Center for Innovation \& Bioinformatics (CIB) within the Neurological Clinical Research Institute at Massachusetts General Hospital.

Time frame: Deidentified participant data may be requested after the study has completed data cleaning and analysis, starting in January 2029

Access criteria: Requests for data from this repository are made through the CIB.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2028, 22 months later.

Of 37 observational studies under Supranuclear Palsy, Progressive, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 54. This study's planned 22 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Jun 2026 → Jan 2027 and primary completion Jul 2028 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2025
First posted
Nov 21, 2025
StartEst.
Jan 15, 2027was Jun 2026
Primary completionEst.
Dec 1, 2028was Jul 2028
CompletionEst.
Jan 1, 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 15, 2026→Jan 15, 2027
Oct 13, 2026
Primary completion
Jul 1, 2028→Dec 1, 2028
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Start date Jun 15, 2026→Jan 15, 2027
    Primary completion Jul 1, 2028→Dec 1, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07240805
Lead sponsor
BioSensics
Responsible party
Sponsor
First posted
Nov 21, 2025
Start date
Jan 15, 2027 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Ana Enriquez
Contact
ana.enriquez@biosensics.com
888-589-6213

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion